Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer

Inclusion Criteria: * Diagnosis of invasive ductal or lobular breast cancer. * Previously untreated (no chemotherapy or hormonal therapy or radiation therapy) invasive breast cancer. * no anti-Her2 therapy if HER2 positive ( defined as 3+ IHC or FISH positive) * Performance Status ECOG \<2 * Age \> 18 years * Tumor \> 2.0 cm by MRI and/or sonographic or clinical exam measurements.or Karnofsky \>50% * Lab test : * Absolute neutrophil count \> 1,500/mm3 * Total Bilirubin ≤ 2×ULN * AST and ALT ≤ 2.5×ULN * serum creatinine ≤ 1.5×ULN Exclusion Criteria: * Pregnant or breast feeding patients are excluded * stage Ⅳ breast cancer * History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon,melanoma in situ, and basal cell and squamous cell carcinomas of the skin * uncontrolled cardiac disease * Active infection or chronic infection requiring chronic suppressive antibiotics * History of hypersensitivity reaction to investigating drugs